The increase in price target from $72 to $82 by Guggenheim suggests a positive outlook on Revolution Medicines' future performance. Maintaining a Buy rating indicates continued confidence from the analyst, which is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.